Preferred Label : Calotatug Ginistinag;
NCIt synonyms : HER2-targeted STING Agonist ADC XMT-2056; STING Agonist ADC XMT-2056; Anti-HER2-STING Agonist Antibody-drug Conjugate XMT-2056; Anti-HER2-STING Agonist ADC XMT-2056;
NCIt definition : An antibody-drug conjugate (ADC) composed of HT-19, a monoclonal antibody directed
against the tumor-associated antigen (TAA) human epidermal growth factor receptor
2 (EGFR2; HER2; ErbB2), linked to a payload composed of an agonist for the stimulator
of interferon genes protein (STING; transmembrane protein 173; TMEM173), with potential
immuno-activating and antineoplastic activities. Upon intravenous administration of
calotatug ginistinag, the anti-HER2 antibody moiety targets and binds to HER2 while
the STING agonist targets and binds to STING on immune cells in the tumor microenvironment
(TME). This allows for specific activation of the STING pathway in the TME. This leads
to the production of pro-inflammatory cytokines, including interferons (IFNs), enhances
the cross-presentation of tumor-associated antigens (TAAs) by dendritic cells (DCs),
and induces a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer
cells. STING, a transmembrane protein that activates immune cells in the TME, plays
a key role in the activation of the innate immune system. The conjugation of the anti-HER2
antibody to the STING agonist improves targeted delivery of the STING agonist and
increases tumor exposure and enhances the STING-mediated anti-tumor immune responses
while limiting systemic toxicity.;
UNII : RA7UQ7N2QE;
CAS number : 2847102-44-5;
Molecule name : XMT-2056; XMT 2056;
NCI Metathesaurus CUI : CL1799031;
Origin ID : C190297;
UMLS CUI : C5783614;
Semantic type(s)
- concept_is_in_subset
- has_target
